Monday, June 29, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Jun 26, 2026
Chutes & Ladders—EMD Serono taps in new commercial strategy head
background ▾
- •This is a personnel/organizational news roundup with no material implications for clinical development, regulatory approval timelines, or commercial performance
EMD SeronoMerck KGaAIpsen Biopharmaceuticalsdaraxonrasib
→ Read original articlePolicy•STAT News•Jun 29, 2026
Opinion: STAT+: The U.S.-China biotech crackdown may hurt the scientists America needs the most
background ▾
- •China now leads the U.S. in share of global drugs in clinical development (34% vs. 27%) and accounts for 40% of new drugs entering clinical stage annually, representing a structural shift in global pharmaceutical innovation
- •U.S.-China biotech restrictions risk deterring international scientific collaboration and talent mobility at a time when the U.S. depends on Chinese-origin scientists and researchers
- •Monitor how U.S. regulatory and trade policy evolves to balance legitimate national security/IP concerns against competitiveness and scientific talent attraction
Policy•STAT News•Jun 29, 2026
Opinion: Banning gender-affirming care doesn’t protect children — it makes it harder to help them
background ▾
- •ASPS's February position statement against gender-affirming surgery for under-19 patients has created a chilling effect, with surgeons reporting discomfort providing such care even when previously selective—contributing to a de facto nationwide ban despite the statement discouraging criminalization.
- •The Trump administration is weaponizing the ASPS statement as validation while escalating legal threats (federal subpoenas, grand jury investigations) against providers, contradicting evidence-based guidelines from major medical organizations (AAP, AMA).
- •Monitor whether this trend spreads to other surgical and medical specialty societies, and whether payers (Medicare/Medicaid) reverse coverage decisions or hospitals restrict protocols under regulatory pressure.
Policy•STAT News•Jun 27, 2026
Opinion: Supreme Court ruling on Roundup points to a confusing difference between the law and science
background ▾
- •The Supreme Court's Monsanto ruling is a legal decision on federal preemption of state warning claims, not a scientific determination of glyphosate safety or carcinogenicity—a critical distinction lost in public discourse
- •Epidemiological causation (population-level probabilistic inference requiring replication and dose-response evidence) differs fundamentally from legal causation (whether a specific injury would probably not have occurred without the defendant's conduct), creating systemic confusion in product liability litigation
- •Watch how this framework influences ongoing talc litigation and future regulatory-litigation disputes, particularly when international agencies (IARC) classify substances differently than US regulators (EPA/EFSA)
MonsantoJohnson & Johnsonglyphosate/Rounduptalc
→ Read original articlePolicy•KFF•Jun 26, 2026
Medicaid/CHIP Monthly Enrollment Tracker
background ▾
- •The 2025 reconciliation law implements the first-ever work requirements for Medicaid expansion enrollees, projected to be the largest source of enrollment declines and expected to significantly reduce the Medicaid-covered patient population beginning January 2027
- •Medicaid/CHIP enrollment has stabilized around 80 million after declining from a pandemic peak of 94 million in March 2023, but new policy requirements threaten renewed contraction that will reshape pharma market size and payer dynamics
- •Pharma companies must prepare for downstream effects: reduced Medicaid patient populations, potential shifts in disease burden and treatment patterns among remaining enrollees, and changing payer negotiations as CMS manages a smaller eligible population
Market Access
Market Access•Fierce Biotech•Jun 26, 2026
Biogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyout
background ▾
- •Biogen is terminating most legacy Apellis R&D programs post-acquisition to concentrate resources on commercializing Empaveli and Syfovre, signaling a near-term revenue focus over pipeline diversification
- •Clinical-stage APL-3007 (siRNA) remains under evaluation while kidney disease indications are suspended, indicating uncertainty about the strategic fit of Apellis' non-complement programs
- •Watch for: Syfovre and Empaveli launch trajectory and competitive positioning; potential partnerships or asset sales for abandoned programs; impact on remaining Apellis talent retention
BiogenApellisBeam TherapeuticspegcetacoplanEmpaveliSyfovre
→ Read original articleMarket Access•Endpoints News•Jun 27, 2026
Pfizer’s Seagen bet sours further; China debate continues to heat up; and more
background ▾
- •Pfizer's Seagen acquisition is generating negative momentum, raising questions about the strategic rationale and integration success of this major oncology bet
- •China market dynamics remain a contentious issue across the pharma industry with unresolved regulatory and commercial implications
PfizerSeagen
→ Read original articleMarket Access•Endpoints News•Jun 26, 2026
FDA approves Viridian eye drug, stoking competition with Amgen's Tepezza
background ▾
- •FDA approval of veligrotug marks the first significant competitive challenge to Amgen's Tepezza monopoly in thyroid eye disease, a rare but high-value indication
- •Competitive landscape shift may pressure Tepezza pricing and create differentiation opportunities based on efficacy, safety, dosing convenience, or patient subpopulation targeting
- •Watch for rapid health plan coverage determinations, comparative effectiveness narratives, and Amgen's commercial response to defend market position
Viridian TherapeuticsAmgenveligrotugLumvoaTepezza
→ Read original articleMarket Access•Fierce Biotech•Jun 26, 2026
The deal before the deal
background ▾
- •BD&L landscape is evolving with increased emphasis on relationship-building and due diligence before formal deal announcements
Haiku BiosciencesMerckNimbus Therapeutics
→ Read original articleMarket Access•Fierce Biotech•Jun 26, 2026
Cardiac medtech HeartBeam drops CEO in restructuring aimed at global ECG platform push
background ▾
- •HeartBeam is transitioning from regulatory approval (December 2023 FDA 510(k)) to commercialization phase, with leadership changes focused on scaling global distribution and market penetration
- •The company is pursuing expansion beyond arrhythmia detection into heart attack and comprehensive cardiac condition detection through planned clinical studies, suggesting potential label expansion strategy
- •Leadership restructure indicates execution challenges or strategic pivot—CEO departure mid-commercialization is a red flag for investors regarding operational stability
HeartBeam
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jun 26, 2026
Epicrispr gene silencer is 1st drug to boost muscle in form of muscular dystrophy, biotech says
background ▾
- •EPI-321 is the first drug candidate to demonstrate measurable muscle mass increase in FSHD patients, addressing a disease with ~870,000 patients globally and no approved therapies
- •Competitors' FSHD programs have failed or disappointed: Sanofi/Fulcrum's losmapimod failed phase 3; Roche/Genentech terminated a phase 2 trial of emugrobart; Epicrispr's claimed clinical first gives it a significant early-stage advantage
- •Watch for: continued enrollment and phase 1/2 readouts; whether muscle gains persist beyond six months; comparator data (a 2025 hormone study showed 4.5 lb gains, raising the bar for clinical relevance); regulatory pathway and potential accelerated designation
Epicrispr BiotechnologiesSanofiFulcrum TherapeuticsEPI-321losmapimodemugrobart
→ Read original articleClinical Trials•Fierce Biotech•Jun 29, 2026
AstraZeneca unveils phase 3 bone disease data behind $5B forecast for Strensiq successor
background ▾
- •Efzimfotase alfa met primary endpoint in Mulberry (RGI-C 1.67 vs. 0 on placebo at Week 25) and demonstrated non-inferiority to Strensiq in the Chestnut switch trial, supporting potential label expansion in pediatric HPP.
- •The Hickory trial failure in adolescents and adults (≥12 years) contradicts the $3–5B peak sales forecast; Alexion argues secondary endpoints justify use despite negative primary 6MWT endpoint, but regulatory/payer acceptance of this rationale remains uncertain.
- •Efzimfotase alfa's reduced dosing frequency (every two weeks vs. three to six times weekly for Strensiq) is a commercial advantage if efficacy/safety parity holds; watch for Hickory full data release and regulatory feedback on the older-age population.
AstraZenecaAlexionefzimfotase alfaStrensiq
→ Read original articleClinical Trials•Fierce Biotech•Jun 26, 2026
Moderna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pathogenic cells
background ▾
- •Moderna is entering in vivo CAR-T with mRNA-6007, targeting CD7+ cells to eliminate pathogenic B cells—a potentially disruptive approach that could overcome manufacturing and accessibility barriers of ex vivo CAR-T therapies
- •The company views autoimmune disease (particularly lupus) as the ideal indication to launch its in vivo CAR-T platform, citing large commercial opportunity, large confirmatory trial potential, and Moderna's unique mRNA-LNP manufacturing scale advantage
- •Clinical development expected to initiate in 2025 following IND-enabling studies and pre-submission regulatory engagements; success of mRNA-6007 will determine confidence in applying in vivo CAR-T to oncology and T-cell reprogramming programs
ModernamRNA-6007
→ Read original articleClinical Trials•Endpoints News•Jun 26, 2026
Akeso pushes back on ASCO questioning of lung cancer drug
background ▾
- •Akeso's lung cancer drug faced public questioning at ASCO, a major oncology forum, indicating potential clinical or methodological concerns requiring company response
- •The need for leadership to 'push back' suggests skepticism from the oncology community that could affect future trial progression, investor confidence, or regulatory pathway
AkesoAkeso lung cancer drug (INN/brand name not specified)
→ Read original articleClinical Trials•Endpoints News•Jun 26, 2026
Lycia raises $75M for food allergy and Graves’ disease
background ▾
- •Lycia has secured $75M in funding to develop protein degradation-based therapeutics for food allergy and Graves' disease
- •The company is led by Nobel Prize winner Carolyn Bertozzi, enhancing its scientific credibility and platform differentiation
Lycia Therapeutics
→ Read original article